Trademark: 79155972
Word
DBV TECHNOLOGIES
Status Date
Friday, May 6, 2022
Registration Number
4834100
Registration Date
Tuesday, October 20, 2015
Filing Date
Friday, July 18, 2014
Published for Opposition
Tuesday, August 4, 2015
Cancellation Date
Friday, May 6, 2022
5 Medicated adhesive devices in the nature of epicutaneous patches for enabling cutaneous or epicutaneous administration of medicated or pharmaceutical substances in powder form for humans and animals for the treatment of allergies, inflammatory and autoimmune diseases; epicutaneous patches featuring a preparation in powder form for medical purposes for the treatment of allergies, inflammatory and autoimmune diseases; medicated occlusion patches in the nature of epicutaneous patches for enabling the absorption of a medicated substance in powder form via the skin for the treatment of allergies, inflammatory and autoimmune diseases
44 Medical services that use a desensitization method that uses immunotherapy; medical treatments of allergies, inflammatory and autoimmune diseases via administration of allergens, antigens using a patch to be affixed to the unbroken skin of the patient, thus avoiding the allergen being transferred into the blood; medical treatments of allergies, inflammatory and autoimmune diseases that use the epicutaneous method of desensitization via immunotherapy; epicutaneous medical treatments of allergies, inflammatory and autoimmune diseases without prior preparation of the skin other than for simple, light cleansing to keep the cellular structure of the epidermis intact; medical consultancy in the field of desensitization to allergies relating to desensitization to combat allergies
10 Medical apparatus, instruments and devices, namely, epicutaneous patches sold without medication for the cutaneous or epicutaneous administration of substances of medicated or cosmetic substances in powder form for humans or animals; occlusion patch dispensers for medical purposes; medical instruments using the electrostatic properties of a biocompatible support, namely, epicutaneous patches sold without medication
42 Medical and scientific research in the field of immunotherapy, namely, designing scientific methods for epicutaneous immunotherapy, inflammatory and autoimmune diseases without prior preparation of the skin other than simple and light cleaning in order to leave the cell structure of the skin intact; scientific research in the field of treating and caring for allergies; scientific research in the field of allergy treatment for a treatment to be applied repeatedly to the skin of the patient without prior preparation of the skin other than simple and light cleaning in order to leave the cell structure of the skin intact and thus avoiding the passage of the allergen into the blood; drug discovery services for the discovery of allergen drugs; medical and scientific research, namely, designing methods for treating allergies via the combination of allergens with immune cells in the skin; medical and scientific research, namely, designing methods for treating allergies, inflammatory and autoimmune diseases via the application of a patch to the unbroken skin of the patient without prior preparation of the skin other than simple and light cleaning in order to leave the cell structure of the skin intact
The mark consists of a blue, partially-shaded square having two concentric circles above a wavy line above the letters "DBV" all positioned above the blue stylized wording "TECHNOLOGIES". The color white appearing in the circles, wavy line and letters "DBV" forming the negative space within the blue square represents transparent areas not claimed as part of the mark.
The color(s) blue is/are claimed as a feature of the mark.
"TECHNOLOGIES"
Dec 12, 2014
Non-Final Action Written
Dec 13, 2014
Non-Final Action (Ib Refusal) Prepared For Review
Dec 4, 2014
Sn Assigned For Sect 66a Appl From Ib
Dec 8, 2014
New Application Office Supplied Data Entered
Dec 8, 2014
Assigned To Examiner
Dec 12, 2014
Application Filing Receipt Mailed
Apr 13, 2015
Correspondence Received In Law Office
Dec 16, 2014
Refusal Processed By Mpu
Dec 16, 2014
Non-Final Action Mailed - Refusal Sent To Ib
Jan 4, 2015
Refusal Processed By Ib
Jan 26, 2015
Teas Response To Office Action Received
Jan 26, 2015
Correspondence Received In Law Office
Jan 26, 2015
Teas/Email Correspondence Entered
Feb 22, 2015
Final Refusal Written
Feb 23, 2015
Final Refusal Mailed
Apr 13, 2015
Teas Request For Reconsideration Received
Apr 14, 2015
Teas/Email Correspondence Entered
Jun 27, 2015
Law Office Publication Review Completed
Apr 29, 2015
Action Continuing A Final - Completed
Apr 29, 2015
Continuation Of Final Refusal Mailed
May 21, 2015
Assigned To Examiner
Jun 1, 2015
Teas Request For Reconsideration Received
Jun 1, 2015
Correspondence Received In Law Office
Jun 1, 2015
Teas/Email Correspondence Entered
Jun 10, 2015
Approved For Pub - Principal Register
Jun 27, 2015
Assigned To Lie
Apr 15, 2016
Final Decision Transaction Processed By Ib
Jul 15, 2015
Notice Of Publication
Aug 4, 2015
Published For Opposition
Sep 10, 2015
Teas Post Publication Amendment Received
Sep 16, 2015
Assigned To Petition Staff
Sep 16, 2015
Changes/Corrections After Pub Approval Entered
Oct 20, 2015
Registered-Principal Register
Jan 20, 2016
Final Disposition Notice Created, To Be Sent To Ib
Feb 29, 2016
Generic Madrid Transaction Created
Feb 29, 2016
Generic Madrid Transaction Sent To Ib
Nov 1, 2021
New Representative At Ib Received
Mar 20, 2023
Total Invalidation Processed By The Ib
May 4, 2017
Change Of Name/Address Rec'd From Ib
May 6, 2022
Cancelled Section 71
Jan 6, 2023
Total Invalidation Of Reg Ext Protection Created
Feb 24, 2023
Invalidation Processed
Feb 24, 2023
Total Invalidation Of Reg Ext Protection Sent To Ib
Jun 15, 2024
New Representative At Ib Received
Trademark Alertz updated from USPTO on 2030-01-24
